Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy‐mediated drug resistance in ovarian cancer cells, xenografts, and patient‐derived xenograft models
Open Access
Abstract
Background: Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors exhibit promising activity against ovarian cancers, but their efficacy can be limited by acquired drug resistance. This study explores the role of autophagy in regulating the sensitivity of ovarian cancer cells to PARP inhibitors.Methods: Induction of autophagy was detected by punctate LC3 fluorescence staining, LC3I to LC3II conversion on Western blot analysis, and electron microscopy. Enhanced growth inhibition and apoptosis were observed when PARP inhibitors were used with hydroxychloroquine, chloroquine (CQ), or LYS05 to block the hydrolysis of proteins and lipids in autophagosomes or with small interfering RNA against ATG5 or ATG7 to prevent the formation of autophagosomes. The preclinical efficacy of the combination of CQ and olaparib was evaluated with a patient‐derived xenograft (PDX) and the OVCAR8 human ovarian cancer cell line.Results: Four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) induced autophagy in a panel of ovarian cancer cells. Inhibition of autophagy with CQ enhanced the sensitivity of ovarian cancer cells to PARP inhibitors. In vivo, olaparib and CQ produced additive growth inhibition in OVCAR8 xenografts and a PDX. Olaparib inhibited PARP activity, and this led to increased reactive oxygen species (ROS) and an accumulation of γ‐H2AX. Inhibition of autophagy also increased ROS and γ‐H2AX and enhanced the effect of olaparib on both entities. Treatment with olaparib increased phosphorylation of ATM and PTEN while decreasing the phosphorylation of AKT and mTOR and inducing autophagy.Conclusions: PARP inhibitor–induced autophagy provides an adaptive mechanism of resistance to PARP inhibitors in cancer cells with wild‐type BRCA, and a combination of PARP inhibitors with CQ or other autophagy inhibitors could improve outcomes for patients with ovarian cancer.Keywords
Funding Information
- National Foundation for Cancer Research
- Cancer Prevention and Research Institute of Texas (RP110595‐P1, RP 170067)
- National Cancer Institute (CA 135354)
This publication has 31 references indexed in Scilit:
- DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathwayCell Death & Disease, 2012
- The role of PARP in DNA repair and its therapeutic exploitationBritish Journal of Cancer, 2011
- The Role of Autophagy in Cancer: Therapeutic ImplicationsMolecular Cancer Therapeutics, 2011
- Negative regulation of autophagyCell Death & Differentiation, 2010
- Autophagy: cellular and molecular mechanismsThe Journal of Pathology, 2010
- Chloroquine activates the p53 pathway and induces apoptosis in human glioma cellsNeuro-Oncology, 2010
- Regulation of Autophagy by Reactive Oxygen Species (ROS): Implications for Cancer Progression and TreatmentAntioxidants & Redox Signaling, 2009
- Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancerBMC Genomics, 2008
- Sulforhodamine B colorimetric assay for cytotoxicity screeningNature Protocols, 2006
- The Tumor Suppressor PTEN Positively Regulates Macroautophagy by Inhibiting the Phosphatidylinositol 3-Kinase/Protein Kinase B PathwayJournal of Biological Chemistry, 2001